LANTHEUS HOLDINGS INC. - COMMON STOCK

Lantheus Reports Preliminary Fiscal Year 2023 Revenue

09 Jan 2024 06:55:00 By Nasdaq GlobeNewswire

Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

18 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Lantheus to Present at the Jefferies London Healthcare Conference

08 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Lantheus Reports Third Quarter 2023 Financial Results

02 Nov 2023 06:00:01 By Nasdaq GlobeNewswire

Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time

19 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

01 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Lantheus to Present at the Wells Fargo Healthcare Conference

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

03 Aug 2023 06:10:00 By Nasdaq GlobeNewswire

Lantheus Reports Second Quarter 2023 Financial Results

03 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time

20 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

12 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Lantheus to Present at the Jefferies Healthcare Conference

01 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR

23 May 2023 07:30:00 By Nasdaq GlobeNewswire

Lantheus Reports First Quarter 2023 Financial Results

04 May 2023 06:00:03 By Nasdaq GlobeNewswire

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

24 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time

20 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Lantheus Announces Two Key Executive Promotions

17 Mar 2023 07:35:00 By Nasdaq GlobeNewswire

Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results

23 Feb 2023 06:00:02 By Nasdaq GlobeNewswire

Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

16 Feb 2023 07:30:00 By Nasdaq GlobeNewswire